Kissei PharmaceuticalKISSEI PHARMACEUTICAL CO.,LTD.4547東証プライム医薬品FY ending Mar 2026, consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Pharmaceutical products | +6.7%5y | 54,147-4.8% | 56,243-3.9% | 63,3484.1% | 75,2996.2% | 77,950-5.8% |
| Information Service | +10.9%5y | 7,74211.8% | 8,28510.6% | 8,39912.7% | 8,7357.3% | 14,2377.7% |
| Construction contracting | — | 2,9486.5% | 2,3433.3% | 3,0228.6% | — | — |
| Trading business | +7.8%5y | 5435.5% | 6213.4% | 80910.0% | 86011.5% | 88615.3% |
| Construction and Facility Maintenance Business | +19.7%2y | — | — | 3,0228.6% | 3,43513.4% | 4,33113.7% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書-第81期(2025/04/01-2026/03/31)
EDINET (FSA Japan)
有価証券報告書-第80期(2024/04/01-2025/03/31)
EDINET (FSA Japan)
有価証券報告書-第79期(2023/04/01-2024/03/31)
EDINET (FSA Japan)
有価証券報告書-第78期(2022/04/01-2023/03/31)
EDINET (FSA Japan)
訂正有価証券報告書-第77期(令和3年4月1日-令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書-第76期(令和2年4月1日-令和3年3月31日)
Extracted from XBRL: 53 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.